



Cos'è AdisInsight?

Presenta il panorama completo dello sviluppo di nuovi farmaci, a partire dagli stadi precoci di ricerca fino allo sviluppo clinico e agli aspetti di *safety* osservati successivamente alla messa in commercio.

Home Page

What's New

More Priority Status Added

You can now identify drug development programs with accelerated status including Regenerative...

Protecting Your Online Privacy

We have removed all 3rd party tracking cookies from AdisInsight to insure the privacy of our users....

Remote Access Help

There are several options available to help our end users access AdisInsight while working remotely....



Ask the Expert

Do you need help? Please contact one of our AdisInsight experts. We aim to get back to you with personalized answer within 24 hours

Name *

Email address *

Question / Comment *

Submit

Coronavirus Drug Profiles

To support Covid-19 research we have made all related AdisInsight content freely available. Below are the 5 most viewed profiles and a link to hundreds more in the database.

- Lenzilumab - Humanigen
- Bamlanivimab - Abcellera/Eli Lilly and Company
- KAND 567
- Remdesivir - Gilead Sciences
- Dapagliflozin - AstraZeneca

[See all drug programs](#)

Coronavirus Trial Profiles

To support Covid-19 research we have made all related AdisInsight content freely available. Below are the 5 most viewed profiles and a link to hundreds more in the database.

- A Phase III Randomized Placebo-Controlled Study to Examine t...
- A Multicenter, Adaptive, Randomized Blinded Controlled Trial of ...
- A Pragmatic Adaptive Open Label, Randomized Phase II/III Mult...
- An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Co...
- A Randomized, Double-blind, Placebo-controlled Phase II Clinic...

[See all trial programs](#)

L'Home Page presenta una barra di ricerca al di sotto della quale è possibile accedere a vari contenuti:

- Novità
- Ask the Espert, per informazioni riguardanti la banca dati
- Sezione a destra che riguarda il Coronavirus

Home Page

Sulla pagina iniziale, in primo piano, è presente la **Barra di ricerca** che permette di interrogare la banca dati per nome del farmaco, indicazione terapeutica, meccanismo d'azione, classe farmaceutica ed eventi avversi.

Home • My Workspace • Contact Us


My Workspace

Personalization | Saved Searches | Alerts

Default Content Set

Drugs
 Trials
 Safety report
 Deals
 Patents

My Workspace è una sezione che permette di personalizzare la visione dei risultati, salvare le ricerche e impostare alcuni alert, ad esempio per notizie o Trials in conclusione



adisinsight.springer.com

Sign up / Log in | Springer

Home • My Workspace • Contact Us

Find your Insights
Make better informed strategic decisions with accurate, interlinked narratives about drug development

by Drug Name Search

Advanced Search | Structure Search | Last 5 Searches

by Drug Name
by Indication
by Mechanism
by Drug Class
by Adverse Event
All Text

Feedback

Home Page

La sezione di ricerca presenta tre sottocategorie:

by Drug Name ▼ 🔍

Advanced Search
Structure Search
Last 5 Searches

Advanced Search

All Search Criteria

- A Adverse Event
- B Biomarker Name
Biomarker Function
- D Drug Class
Drug Name
- E EPhMRA code
- F Formulation
Full Text
- H Highest Phase
- I Indication
Investigator
- J Journal Name
- L Location
- M Mechanism of Action
- O Organisation
Organisational Role
Organisation Type
- U Update Date
Update Type
- W WHO ATC code
- P Patient Segment
Phase
Publication Country

Italy Add

Your query

Indication × Is ▼ Hypertension ×

AND

Phase × Is ▼ Phase IV ×

Filter by Apply filters

resulted in approximately

0	722	0	0	0
Drugs	Trials	Safety Reports	Deals	Patents
Reset Show Results				

Search by Structure

Start by drawing a structure Advanced Search

Upload a structure (MOL file) Scopri file Nessun...zonato Download structure

Reset ↶ ↷ ↺ ↻ ↵ ↶ ↷ ↺ ↻ ↵ ↶ ↷ ↺ ↻ ↵ ↶ ↷ ↺ ↻ ↵ Show Results

Da questa sezione si può risalire alle ultime cinque ricerche effettuate

Fare una **ricerca avanzata** significa interrogare la banca dati in maniera più ampia, aggiungendo dei campi di interesse, come “eventi avversi”, “Data di fine trial”, “Meccanismo d’azione” etc...

È possibile fare una ricerca anche per **struttura**

Ricerca

Qualunque metodo di ricerca si utilizzi la schermata visualizza i risultati in cinque Tab: Farmaci, Trials, Report di sicurezza, Accordi e Brevetti

The screenshot shows the Adis Insight search results for 'Bisoprolol'. The search bar is at the top left, and the results are displayed in a tabbed format. The 'Drugs' tab is active, showing 14 results. A sidebar on the left allows refining the search by Indication and Phase. The main results area shows 'Ritobegron' with details like 'Beta 3 adrenergic receptor agonists' and 'Originator: Kissei Pharmaceutical | Licensed by: Boehringer Ingelheim'. Navigation options like 'Export', 'Analysis', and 'Print Selected 0 drugs' are visible.

Si possono applicare i filtri

La ricerca può essere visualizzata con tutti i filtri, condividerla tramite URL e modificarla

Ci sono poi degli strumenti di esportazione della ricerca in file excell o PDF; costruire un'analisi tabellare dei risultati con singoli o più parametri; stampare; carattere.

Ricerca- Tab “Drugs”

Selezionando una voce dei risultati vengono visualizzate tutte le informazioni suddivise in sezioni

adinsight.springer.com/drugs/800024558

Adis Insight

Search: by Drug Name Bisoprolol

Home · My Workspace · Contact Us

Drug Profile

Bisoprolol

Alternative Names: Bisoprolol fumarate, Concor, Maintate, TA-4708

Latest Information Update: 12 Jul 2020

Print Profile Download Citation

Chemical structure: CC(C)OCCOCCOC1=CC=C(C=C1)C(O)CNC

Table of Contents

At a glance

Originator	Merck KGaA
Developer	Merck KGaA; Mitsubishi Tanabe Pharma Corporation
Class	Antihypertensives; Heart failure therapies; Ischaemic heart disorder therapies; Propanolamines; Small molecules
Mechanism of Action	Beta 1 adrenergic receptor antagonists
Orphan Drug Status	No
New Molecular Entity	No

Table of Contents

At a glance

Development Overview

Introduction

Company agreements

Key development milestones

Drug Properties & Chemical Synopsis

Biomarker

Trial Landscape

Development Status

Summary Table

Related Drugs

Commercial Information

Involved Organisations

Brand Names

Credit Suisse Market Status

Credit Suisse Financial Forecast

Related Safety Reports

Development History

References

Ricerca- Tab “Trials”

I Trials si possono trovare in diversi status segnati in arancione

- Status see all	
<input type="checkbox"/> Completed	71
<input type="checkbox"/> Recruiting	19
<input type="checkbox"/> Discontinued	18
<input type="checkbox"/> Active, no longer recruiting	9
<input type="checkbox"/> Planning	7

The screenshot shows the Adis Insight search interface. The search term is 'Transcriptional elongation factor inhibitors'. The results are filtered by 'Phase' and 'Status'. The 'Status' filter is expanded, showing the following counts:

- Status see all	
<input type="checkbox"/> Completed	71
<input type="checkbox"/> Recruiting	19
<input type="checkbox"/> Discontinued	18
<input type="checkbox"/> Active, no longer recruiting	9
<input type="checkbox"/> Planning	7

The main results list shows two trials:

- Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia** (17 Feb 2021). Status: **Completed**. Drugs: Alvocidib (Primary), Venetoclax (Primary). Indications: Acute myeloid leukaemia. Phase of Trial: Phase I.
- A Phase 1, Open-Label, Multicentre, Non-Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD4573, a Potent and Selective CDK9 Inhibitor, in Subjects With Relapsed or Refractory Haematological Malig...** (16 Feb 2021). Status: **Recruiting**. Drugs: AZD-4573 (Primary). Indications: Acute myeloid leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma, Richter's syndrome; T-cell lymphoma.

Ricerca- Tab “Trials”

adinsight.springer.com/trials/700206511

◀ Previous Next ▶

Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2021

» Print Profile » Download Citation

At a glance

Drugs	Dinaciclib (Primary) ; Veliparib (Primary)
Indications	Breast cancer; Solid tumours
Focus	Adverse reactions

Most Recent Events

15 Jan 2021	Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.
22 Jan 2020	Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2020.
29 Nov 2018	Planned number of patients changed from 130 to 118.

Trial Overview

Purpose

Cliccando su uno dei risultati la pagina mostra tutte le caratteristiche dello specifico Trial suddivise in sezioni, con indice a lato

- Table of Contents
- [At a glance](#)
- [Trial Overview](#)
 - Purpose
 - Primary Endpoints
 - Other Endpoints
 - Diseases Treated
 - Subjects
- [Trial Details](#)
 - Identifiers
 - Other Details
 - Related Drugs
- [Interventions](#)
- [Trial Centres](#)
 - Investigators
 - Centres
- [Trial History](#)
- [References](#)

Ricerca- Tab “Safety Report”

La schermata dei risultati dà la possibilità di scegliere le colonne da mostrare: effetti avversi, citazioni, lingua, primo report, paese, numero di casi e data

adinsight.springer.com/search

Adis Insight

Search: by Mechanism Transcriptional elongation factor inhibitors

Advanced Search Structure Search Last 5 Searches

Home My Workspace Contact Us

35 Drugs 132 Trials 33 Safety Reports 31 Deals 0 Patents

Share Query Edit Query Export Analysis Print Selected 0 safety reports

Search results for Mechanism of Action: "Transcriptional elongation factor inhibitors"

Showing 10 of 33 safety reports

Safety Report Name	Serious & First Report	Country	Number of Cases	Release Date
<input type="checkbox"/> Multiple drugs <i>Lymphopenia and varicella zoster virus reactivation: case report</i>	Serious	USA	1	28 Oct 2020
<input type="checkbox"/> Hydroxychloroquine/mepacrine <i>Hyperpigmentation: case report</i>	-	USA	1	23 Sep 2020
<input type="checkbox"/> Multiple drugs <i>Off-label use: case report</i>	-	Kuwait	1	07 Jul 2020
<input type="checkbox"/> Mepacrine <i>Off-label use: 36 case reports</i>	-	Spain	36	07 May 2019
<input type="checkbox"/> Mepacrine <i>Yellow skin discolouration and itching: 2 case reports</i>	-	Spain	2	07 May 2019

Attiva Windows
Passa a Impostazioni per attivare Windows

Ricerca- Tab “Safety Report”

Drug Safety : ADR Case Report

Multiple drugs

Lymphopenia and varicella zoster virus reactivation: case report

Serious

Release Date: 28 Oct 2020

[Print Report](#) [Download Citation](#)

Narrative Summary

A 54-year-old woman developed lymphopenia and varicella zoster virus (VZV) reactivation following treatment with prednisone, mycophenolate mofetil, mepacrine and methylprednisolone for systemic lupus erythematosus (SLE) or presumed exacerbation of SLE [not all routes and outcomes stated; dosages and time to reaction onsets not stated].

The woman presented with fatigue, myalgia, progressive leg weakness for several weeks and acute vision loss in left eye. Anamnesis revealed that she had SLE which was being actively treated with prednisone, mycophenolate mofetil and mepacrine (quinacrine). Her medical history was also significant for VZV infection in childhood. Initially, her symptoms were presumed to be due to exacerbation of SLE. Therefore, she started receiving IV methylprednisolone and plasma exchange. Following a week of this treatment, she developed hearing changes, acute vision loss in her right eye and difficulty swallowing. Due to progression of symptoms, she was hospitalised. Upon admission, neurologic examination revealed normal mental status. The cranial nerve examination revealed absent light perception bilaterally, severe diffuse ophthalmoparesis, nonreactive pupils, loss of facial sensation in the left V1 and V2 trigeminal distribution, and diminished hearing to finger rubbing on the right and right palate deviation. She exhibited motor deficits in the form of mild bilateral upper extremity weakness and paraplegia. Deep tendon reflexes were noted to be pathologically exaggerated in the upper extremities, but absent in the lower extremities. Vibratory sensation was decreased throughout all four limbs. Pinprick sensation was reduced in the lower limbs in association with a sensory level at T10. Laboratory investigation revealed lymphopenia, positive double-stranded DNA antibody and mildly reduced levels of C3 and C4 complement. Lymphopenia was thus suspected to be related to prednisone, mycophenolate mofetil, mepacrine and methylprednisolone. Brain MRI showed multifocal non-enhancing parenchymal lesions and patchy, non-continuous enhancements of multiple cranial nerves (optic chiasm, left III, bilateral V, and right VIII), in conjunction with leptomeningeal enhancement. MRI of the spine revealed T2 signal prolongation, spanning the level from T2 to the conus medullaris. The enhancement pattern was restricted to the caudal aspect of the spinal cord. CSF examination revealed xanthochromia, elevated total protein and 6 CSF-restricted oligoclonal bands. Ophthalmologic consultation showed bilateral disseminated retinal nerve fiber layer lesions, most consistent with cotton wool spots, in conjunction with multifocal retinal haemorrhages. This findings were most consistent with severe, bilateral, outer retinal necrosis. She had developed disseminated and pathologic cataplectic syndrome that included subacute paraplegia (the derivative of a centrally predominant and longitudinally extensive, oedematous, transverse myelitis [LETM] with multiple areas of patchy focal enhancement on MRI), bilateral cranial neuropathies, and bilateral optic nerve involvement with severe retinal necrosis. A subsequent PCR testing of CSF revealed VZV infection. Based on the investigational findings, clinical presentation and prior history of VZV infection, she was diagnosed with VZV reactivation resulting in oculo-meningo-encephalo-myeloradiculitis and VZV vasculopathy. The VZV reactivation was considered to have developed secondary to immunosuppressive therapy (prednisone, mycophenolate mofetil, mepacrine and methylprednisolone).

Country and Language

Reporter Country	USA
Country Of Publication	USA
Language	English

Descriptors

Drugs	Mepacrine adverse reactions (Serious) Methylprednisolone adverse reactions (Serious) Mycophenolate mofetil adverse reactions (Serious) Prednisone adverse reactions (Serious)
Drug Class	Acyclic acids Aminoacridines Anti-inflammatories Antiallergics Antilasthmatics Antimalarials Antineoplastics Antiprotozoals Antirheumatics Corticosteroids Fatty acids Glucocorticoids Pregnadienediols Pregnadienetriols Small molecules
Adverse Reactions	Lymphopenia drug-induced Varicella zoster virus infections drug-induced
Route of Administration	Intravenous
Category	Adverse Event

Selezionando uno dei risultati la pagina ci restituisce: la descrizione del caso clinico, paese e lingua, descrizione del farmaco in questione, farmaci correlati e bibliografia.

Ricerca- Tab “Deals”

Refine Your Search

- Deal Type [see all](#)
 - Licensing 5
 - Marketing agreement 4
 - R&D agreement 4
 - Acquisition 1
 - Development and marketing agreement 1
- Organisation [see all](#)
 - Actelion Pharmaceuticals 5
 - Johnson & Johnson 5
 - Boston Therapeutics 4
 - Advance Pharmaceutical Co Ltd 2
 - HK inno N 2
- Indication [see all](#)
 - Diabetes mellitus 3
 - Gaucher's disease 3
 - Viral infections 3
 - Hepatitis C 2
 - Cancer 1
- + Mechanism Of Action [see all](#)
- + Update Date

21 Drugs	189 Trials	102 Safety Reports	18 Deals	2 Patents
----------	------------	--------------------	----------	-----------

[Show Query](#) [Share Query](#) [Edit Query](#) [Export](#) [A](#) [A+](#)

Showing 10 of 18 deals

[Actelion Pharmaceuticals, Johnson & Johnson](#) \$30000 M (USD)

Drugs: ACT 132577, ACT 246475, ACT 539313, ACT 541468, ACT 709478, ACT 774312, Cenerimod, Clazosentan, Lucerastat | **Indications:** Not related

In June 2017, Johnson & Johnson completed the acquisition of Actelion. The acquisition was completed by Johnson & Johnson's Swiss subsidiary, Janssen Holding GmbH, that acquired all publicly held... [See more](#)

R&D agreement - 28 May 2015

[Boston Therapeutics, University of Buffalo](#)

Drugs: BTI 320 | **Indications:** Not related

In May 2015, Boston Therapeutics, signed a Letter of Intent with Dr. Gene D. Morse, Director of the Translational Pharmacology Research Core in the University at Buffalo's Center of Excellence for Bioinformatics and Life Sciences to potentially collaborate on an enrollment program for a preventative clinical trials initiative at several locations in Buffalo, NY and New York City's Chinatown. The purpose of this collaboration initiative is to evaluate the effects of BTI-320 on an individual's HbA1c levels, in particular, who are diabetic and pre-diabetic. [See less](#)

[Advance Pharmaceutical Co Ltd, Boston Therapeutics](#)

Drugs: BTI 320 | **Indications:** Diabetes mellitus

In November 2014, Boston Therapeutics and Advance Pharmaceutical Company, via its subsidiary Sugardown Company Ltd. of Hong Kong, agreed to expand their marketing agreement for Boston Therapeutics' sugardown® to include 12 additional countries in Asia. Under the terms of the original agreement, SugarDown Company Ltd. can market sugardown® in China, Hong Kong and Macau. The new agreement expands the marketing initiative to Korea, Taiwan, Singapore, Thailand, Malaysia, Vietnam, Philippines, Myanmar, Indonesia, Laos, Brunei and Cambodia.

In June 2011, Boston Therapeutics granted Advance Pharmaceutical Company exclusive rights to market and sell SUGARDOWN™ (BTI-320) in China.

Nella Tab “Deals” c’è l’elenco di tutti gli accordi.
Cliccando su “See more” si possono vedere più dettagli riguardo all’accordo selezionato

Ricerca- Tab “Patent”

The screenshot shows the Adis Insight search interface. The search bar contains 'Amiodarone' and the results are filtered by 'Drug Name'. The search results are displayed in a table with columns for 'Drug Patent Profile', 'NDAs / BLAs', 'USA Patents', 'International Patents', and 'Patent Applications'. The results show 1 patent for Amiodarone - Baxter, with 1 NDA/BLA, 9 USA Patents, 51 International Patents, and 699 Patent Applications.

Adis Insight > Sign up / Log in

Search: by Drug Name ▼ Amiodarone Advanced Search Structure Search Last 5 Searches

Home • My Workspace • Contact Us

Refine Your Search

- Patent Location
- Claim Type
- Applicant
- Mechanism Of Action
- Drug Class

5 Drugs 37 Trials 1,697 Safety Reports 0 Deals 1 Patents

Show Query Share Query Edit Query Export A- A A+

Showing 1 of 1 patents

Drug Patent Profile	NDAs / BLAs	USA Patents	International Patents	Patent Applications
<input type="checkbox"/> Amiodarone - Baxter	1	9	51	699

Nei risultati dei brevetti le colonne presentate sono: NDAs/BLAs, quanti brevetti in USA, quanti internazionali e le applicazioni

Ricerca- Tab "Patent"

Amiodarone - Baxter

At a glance

Drug Originator	CyDex Pharmaceuticals
Drug Licenced by	Baxter International, Takeda
Drug Class	Benzofurans; Class III antiarrhythmics; Heart failure therapies; Small molecules
Mechanism of Action	Beta-adrenergic receptor antagonists; KATP channel inhibitors; Sodium channel antagonists
USA Patent Applicants	BAXTER HLTHCARE
USA Patents	9
NDAs	1
International Patents	51
Patent Applications	699

Table of Contents

- [At a glance](#)
- [USA](#)
 - Patents Affecting Generic Entry
 - Non-Orange Book Patents
 - Patent Applications
- [European Union Five \(EU5\)](#)
 - Patents Affecting Generic Entry
- [Japan](#)
 - Patents Affecting Generic Entry
- [Rest Of The World](#)
 - Patents Affecting Generic Entry

Cliccando su uno dei risultati la pagina mostra tutte le caratteristiche dell'accordo specifico suddivise in sezioni, con indice a lato

USA

Patents Affecting Generic Entry

There are 4 patents affecting generic entry in USA.

Patent Number	Claim Types	Title	Filing Date	Loss of Patent	Brand Name	BLA / NDA / ANDA	Applicant	Source
...

Attiva Windows

Passa a Impostazioni per attivare



Back to top

Come accedere?

<https://adisinsight.springer.com/>

Accesso dalle sottoreti del Dipartimento di Scienze del Farmaco, della Biblioteca di Scienze del Farmaco da casa via proxy.

Il fornitore SpringerNature organizza periodicamente seminari di formazione sulla banca dati.

Per informazioni rivolgersi alla Biblioteca di Scienze del Farmaco
biblio.scienzedelfarmaco@unipd.it